Table 4.
Statistical evaluation of pediatric PK model performance
| Model | N | AAFE | R 2 | RMSE | Twofold error |
|---|---|---|---|---|---|
| Inflammatory bowel disease | |||||
| Fasanmade et al. 51 | 580 | 0.77 | 0.977 | 8.1 | 60.8% |
| Fasanmade et al. 52 | 482 | 1.09 | 0.964 | 9.7 | 76.5% |
| Ternant et al. 53 | 33 | 1.35 | 0.980 | 10.1 | 80.4% |
| Dotan et al. 54 | 54 | 0.60 | 0.957 | 21.4 | 51.0% |
| Aubourg et al. 55 | 133 | 1.36 | 0.973 | 8.5 | 82.4% |
| Buurman et al. 56 | 42 | 2.82 | 0.913 | 17.0 | 47.0% |
| Brandse et al. 39 | 332 | 1.18 | 0.970 | 14.0 | 84.3% |
| Rheumatoid arthritis | |||||
| Ternant et al. 57 | 84 | 0.83 | 0.987 | 20.7 | 66.7% |
| All allometric models | |||||
| 1.25 | 13.7 | 68.6% | |||
| PBPK modeling | |||||
| This study | 1.79 | 0.96 | 7.0 | 66.7% | |
AAFE, absolute average fold error; PBPK, physiologically‐based pharmacokinetic; PK, pharmacokinetic; R 2, squared Pearson correlation coefficient; RMSE, root mean squared error.